Mannkind Corporation Reports 2023 First Quarter Financial Results
May 09, 2023 16:00 ET
|
MannKind
1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 1Q 2023 Revenues associated with Tyvaso DPI of $23 million 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million $167 million of...
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
May 02, 2023 17:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a...
Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
March 27, 2023 16:05 ET
|
MannKind
DANBURY, Conn., March 27, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for...
MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023 17:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
February 23, 2023 16:00 ET
|
MannKind
2022 Total Revenues of $100 million; +32% vs. 20212022 Royalties from Tyvaso DPI of $16 million; 4Q 2022 of $9 million4Q 2022 Commercial Products Net Revenue of $17 million;+54% vs. 4Q 2021$173...
MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
February 22, 2023 06:05 ET
|
MannKind
Inhaled Technosphere® Insulin (TI) lowered peak glucose levels 30 minutes faster than injectable rapid-acting insulin delivered through an AID insulin pump and significantly lowered post-prandial...
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
February 16, 2023 17:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 fourth quarter and full year financial results and its...
Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
February 10, 2023 17:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
January 24, 2023 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
January 23, 2023 06:05 ET
|
MannKind
Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side...